Tiziana Life Sciences Ltd
TLSA
Rank in Stocks
#20404
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and... Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Share Price
$0.6691
Last synced: 2026-11-09
Market Cap
$85.15M
Change (1 day)
-2.86%
Change (1 year)
-61.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tiziana Life Sciences Ltd (TLSA)
Category
Healthcare
EPS for Tiziana Life Sciences Ltd (TLSA)
EPS as of June 2026 TTM: $-0.21
According to Tiziana Life Sciences Ltd's latest financial reports, its current EPS (TTM) is $-0.21. At the end of 2025 the company had an EPS of $-0.16, a decrease compared to its 2024 EPS of $-0.11.
EPS history for Tiziana Life Sciences Ltd from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.21 | 31.25% |
| 2025 | $-0.16 | 45.45% |
| 2024 | $-0.11 | -35.29% |
| 2023 | $-0.17 | 13.33% |
| 2022 | $-0.15 | -53.13% |
| 2021 | $-0.32 | -13.51% |
| 2020 | $-0.37 | 439.36% |
| 2019 | $-0.07 | 17.26% |
| 2018 | $-0.06 | -25.19% |
| 2017 | $-0.08 | -6.46% |
| 2016 | $-0.08 | -38.48% |
| 2015 | $-0.14 | -71.86% |
| 2014 | $-0.48 | 2,291.09% |
| 2013 | $-0.02 | -97.35% |
| 2012 | $-0.76 | -16.73% |
| 2011 | $-0.92 | -86.41% |
| 2010 | $-6.74 | 18.30% |
| 2009 | $-5.70 | -82.13% |
| 2008 | $-31.89 | -76.60% |
| 2007 | $-136.29 | -18.93% |
| 2006 | $-168.12 | -25.59% |
| 2005 | $-225.93 | -6.27% |
| 2004 | $-241.06 | -35.68% |
| 2003 | $-374.77 | -53.56% |
| 2002 | $-806.92 | -50.01% |
| 2001 | $-1.61K | -21.92% |
| 2000 | $-2.07K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -7,557.14% |
US
|
|
| $-7.07 | 3,266.67% |
US
|
|
| $-5.29 | 2,419.05% |
AU
|
|
| $12.88 | -6,233.38% |
BE
|
|
| $21.56 | -10,366.67% |
NL
|
Questions about Tiziana Life Sciences Ltd's earnings per share (EPS)
What is Tiziana Life Sciences Ltd's earnings per share (EPS)?
Tiziana Life Sciences Ltd's earnings per share (EPS) over the last twelve months is $-0.21, as of Jun 2026.
What was Tiziana Life Sciences Ltd's earnings per share (EPS) in 2025?
In 2025, Tiziana Life Sciences Ltd's earnings per share (EPS) was $-0.16, compared with $-0.11 in 2024.
How has Tiziana Life Sciences Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tiziana Life Sciences Ltd's earnings per share (EPS) was highest in 2024 ($-0.11) and lowest in 2020 ($-0.37).
How does Tiziana Life Sciences Ltd's earnings per share (EPS) compare with similar companies?
Tiziana Life Sciences Ltd's earnings per share (EPS) ($-0.21) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.